Biologics are a highly effective therapeutic option with broad applicability across many indications. However, the traditional fed-batch manufacturing presents significant challenges, especially when upscaling from clinical to commercial supply. With a modular continuous manufacturing setup, the J.POD® technology allows for highly intensified cGMP manufacturing of biologics at flexibly scalable quantities, thus reducing both scale-up risks and manufacturing costs significantly. Evotec Biologics’ second J.POD® facility marks an important milestone on their path to making biologics globally available.
Value add
Data
Phase 1 - Complete building and fit-out of 14,900 sq.m.; Phase 2 - Fit-out of remaining 700 sq.m.
Ongoing
Ludovic Lecoeur
Associate Director
Paris
Relevant Projects
Latest Insights
16th April 2024
Building sustainability into our DNA - A roundtable discussion
Construction projects in the pharmaceutical industry must contend with the sector's distinct complexities.
Continue Reading21 March 2024
Construction Market Insights - Europe
21 March 2024
Construction Market Insights - Americas
21 March 2024
Construction Market Insights - APAC and GCC